Skip to Content

A Phase Ib study of intermittent administration of high doses of the irreversible EGFR inhibitor afatinib as a means of achieving plasma levels active against non-small cell lung cancer with known T790M mutations

Objective
Not available at this time
IRB Protocol Number
12-0610
Principal Investigator(s)
ROSS CAMIDGE

Cancer Trials

  • Lung Cancer
  • All Cancers
Sponsor(s)
Boehringer Ingelheim Pharmaceuticals, Inc.
Contact
TARA WELLS at 720-848-0755
or TARA.WELLS@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : Not available at this time // Not available at this time